Home » Archive

Articles Archive for August 2011

Antipsychotics »

[8 Aug 2011 | No Comment | 508 views]
XEPLION® (paliperidone palmitate)

European Commission Approves XEPLION® for Treatment of Schizophrenia
Beerse, Belgium (March 9, 2011) — Janssen-Cilag International NV today announced that XEPLION® (paliperidone palmitate), a once monthly, long-acting injectable, antipsychotic, has received approval from the European Commission for the treatment of schizophrenia.
 Schizophrenia is relatively common and the prevalence is similar around the world. The lifetime risk for schizophrenia is estimated to be one person in 100, and appears to be the same for men and women up to age 60 years.[1] Schizophrenia is a devastating mental illness for both the patients …